

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims

1-27. (canceled)

28. (currently amended): Peptide fragment derived from ubiquitidine and comprising a continuous series of ~~at least 3~~ between 6 to 18 amino acids from the amino acid sequence of ubiquitidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPN
ANS, (SEQ ID NO: 1) ~~with the exception of~~ which does not include peptides having the amino acid sequence KVHGSLARAGKVRGQTPKVAKQ (SEQ ID NO: 10) or AGKVRGQTPKVAKQEKKKKKT (SEQ ID NO: 11).

29. (currently amended): Peptide fragment as claimed in claim 28, comprising a continuous series of ~~at least 8~~ between 6 to 18 amino acids from the amino acid sequence of ubiquitidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPN
ANS, (SEQ ID NO: 1) ~~with the exception of~~ which does not include peptides having the amino acid sequence KVHGSLARAGKVRGQTPKVAKQ (SEQ ID NO: 10) or AGKVRGQTPKVAKQEKKKKKT (SEQ ID NO: 11).

30. (currently amended): Peptide fragment as claimed in claim 28, consisting ~~with one~~ of the following amino acid sequences:

ubiquitidine (1-18)	KVHGSLARAGKVRGQTPK (SEQ ID NO: 2)
ubiquitidine (29-41)	TGRAKRRMQYNRR (SEQ ID NO: 3)
ubiquitidine (18-29)	KVAKQEKKKKKT (SEQ ID NO: 4)
ubiquitidine (18-35)	KVAKQEKKKKKTGRAKRR (SEQ ID NO: 5)
ubiquitidine (29-35)	TGRAKRR (SEQ ID NO: 7)

RECEIVED
JAN 30 2004
TECH CENTER 1600/2900

ubiquicidine (42-59) FVNVVPTFGKKKGPNANS (SEQ ID NO: 8)
ubiquicidine (36-41) MQYNRR (SEQ ID NO: 9)

31. (currently amended): Derivative of ubiquicidine or of a peptide fragment derived from ubiquicidine and comprising a continuous series of ~~at least 3~~ between 6 to 18 amino acids from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPNANS, (SEQ ID NO: 1) which derivative has an amino acid sequence which is at least partly the reverse of the amino acid sequence of the corresponding original peptide.

32. (currently amended): Derivative of a ubiquicidine ~~of~~ or of a peptide fragment derived from ubiquicidine and comprising a continuous series of ~~at least 3~~ between 6 to 18 amino acids from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPNANS, (SEQ ID NO: 1) wherein at least one of the amino acids from the original peptide is replaced by a stereoisomer of that amino acid.

33. (currently amended) Derivative of ubiquicidine or of a peptide fragment derived from ubiquicidine and comprising a continuous series of ~~at least 3~~ between 6 to 18 amino acids from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPNANS, (SEQ ID NO: 1) wherein the original amino acid chain is extended at one or both ends thereof with one or more groups, such as D-amino acids, protecting against degradation.

34. (currently amended): Derivative as claimed in claim 33, ~~with the amino acid sequence:~~

~~D-A-KVAKQEKKKKKTGRAKRR-D-A~~ (SEQ ID NO: 6) ~~in which D-A represents D-alanine,~~
wherein the original amino acid chain is extended at one or both ends thereof with one or more groups of D-alanine.

35-40. (canceled)

41. (currently amended): A method for the therapy of an infection in humans and animals, comprising:

a) administering a an antimicrobial compound selected from the group consisting of ubiquicidine, a derivative of ubiquicidine, and a peptide fragment derived from ubiquicidine and comprising a continuous series of ~~at least 3~~ between 6 to 18 amino acids from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVP
TFGKKKGPNANS (SEQ ID NO: 1); and

b) treating the infection, wherein the antimicrobial action of the compound results in inhibiting or otherwise exerting a negative effect on the infection.

42. (currently amended): The method of claim 41, wherein the peptide fragment comprises a peptide fragment, comprising a continuous series of ~~at least 8~~ between 6 to 18 amino acids from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPN
ANS, (SEQ ID NO: 1) with the exception of peptides having the amino acid sequence
KVHGSLARAGKVRGQTPKVAKQ (SEQ ID NO: 10) or AGKVRGQTPKVAKQEKKKKKT
(SEQ ID NO: 11).

43. (currently amended): The method of claim 41, wherein the derivative comprises a ~~derivatives~~, derivative of ubiquicidine or of a peptide fragment derived from ubiquicidine and comprising a continuous series of ~~at least 3~~ between 6 to 18 amino acids from the amino acid sequence of ubiquicidine:

Application No. 09/424,815
Paper Dated January 22, 2004
Reply to USPTO Correspondence of September 23, 2003
Attorney Docket No. 702-991768

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPN
ANS, (SEQ ID NO: 1) which derivative has an amino acid sequence which is at least partly the
reverse of the amino acid sequence of the corresponding original peptide.

44. (canceled)

45. (currently amended): The method of claim 41, wherein the microbial
infection is caused by a ~~cause~~ microorganism selected from the group consisting of Gram-
positive bacteria, Gram-negative bacteria, fungi, and viruses, ~~and parasites~~.

46. (currently amended): Antimicrobial agent, comprising at least a suitable
quantity of one or more active components chosen from ubiquicidine, peptide fragments derived
from ubiquicidine and comprising a continuous series of ~~at least 3~~ between 6 to 18 amino acids
from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPN
ANS (SEQ ID NO: 1).

47. (currently amended): The method of claim 41, wherein the compound
comprises an antimicrobial agent, comprising at least a suitable quantity of one or more active
components chosen from ubiquicidine, peptide fragments derived from ubiquicidine and
comprising a continuous series of ~~at least 3~~ between 6 to 18 amino acids from the amino acid
sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPN
ANS (SEQ ID NO: 1).

48. (canceled)

49. (currently amended): Method for monitoring a treatment, comprising:

Application No. 09/424,815
Paper Dated January 22, 2004
Reply to USPTO Correspondence of September 23, 2003
Attorney Docket No. 702-991768

a) administering an antimicrobial agent, comprising at least a suitable quantity of one or more active components chosen from ubiquicidine, peptide fragments derived from ubiquicidine and comprising a continuous series of ~~at least 3~~ between 6 to 18 amino acids from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVP
TFGKKKGPNANS (SEQ ID NO: 1),

b) observing the localization of the agent in time, and

c) following the effect of the treatment, wherein the antimicrobial action of the compound results in inhibiting or otherwise exerting a negative effect on the infection.

50-54. (canceled)

55. (previously presented): Antimicrobial agent as claimed in claim 46, further comprising at least one excipient.

56-59. (canceled)

60. (currently amended): Method for providing prophylactic action against an infection in humans or animals, comprising:

a) administering a peptide fragment, derived from ubiquicidine and comprising a continuous series of ~~at least 3~~ between 6 to 18 amino acids from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVP
TFGKKKGPNANS, (SEQ ID NO: 1) ~~with the exception of~~ which does not include peptides

Application No. 09/424,815
Paper Dated January 22, 2004
Reply to USPTO Correspondence of September 23, 2003
Attorney Docket No. 702-991768

having the amino acid sequence KVGHSLARAGKVRGQTPKVAQ (SEQ ID NO: 10) or
AGKVRGQTPKVAQEKKKKKKT (SEQ ID NO: 11) in the form of a coating, and

b) ~~providing prophylactic action thereby~~ wherein said administration results in
preventing the infection.